Etanercept biosimilar - Nanogen Biopharmaceutical

Drug Profile

Etanercept biosimilar - Nanogen Biopharmaceutical

Alternative Names: Nanercept

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 17 Mar 2016 Etanercept biosimilar is still under preregistration for Rheumatoid arthritis and Psoriasis in Vietnam (SC)
  • 15 Mar 2016 Biomarkers information updated
  • 12 Mar 2014 Preregistration for Psoriasis in Vietnam (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top